1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | SW-780; SW780 |
| Species | Human |
| Cat.No | ABC-TC1190 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Colon |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Bladder Cancer Cell Lines |
SW 780 is a bladder cancer cell line that originated from a grade I urinary bladder transitional cell carcinoma in an 80-year-old patient back in 1974, following preoperative chemotherapy with Thiotepa. These cells exhibit tumorigenic properties, manifesting the ability to develop tumors in nude mice. Notably, the application of epigallocatechin-3-gallate (EGCG) has proven effective in inhibiting SW 780 cell proliferation and migration by modulating the NF-κB and MMP-9 pathways. The cell line is characterized by a reported plating efficiency of 41%. For subculturing, it is recommended to split the cells at ratios between 1:4 and 1:8, conducted two to three times a week.
Why choose SW 780 from AcceGen?
SW 780 cells from AcceGen are characterized by their high viability and quality. The cell line is meticulously maintained, with daily monitoring to ensure the absence of bacteria and fungi. Additionally, a PCR-based assay is employed to confirm the absence of mycoplasma contamination, and the cell line’s identity is validated through STR analysis, ensuring its authenticity and reliability for research purposes.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
SW 780, a bladder cancer cell line, holds significant utility in the realm of bladder cancer research. It is notably employed in the creation of the CDX (Cell Line Derived Xenograft) SW 780 xenograft mouse model, a pivotal tool facilitating the examination of bladder cancer treatment approaches. This model serves as an invaluable experimental system for rigorously evaluating the potential efficacy of various pharmaceutical agents in modulating bladder tumor growth. The insights gained from these studies contribute substantially to the advancement of novel and targeted therapeutic strategies for the management of bladder cancer.
